FGF2 and prostate carcinoma: For example, the TGF-β-mediated angiogenic effect on xenografts of prostate cancer is regulated by TGFBRII/SMAD3-dependent upregulation of fibroblast growth factor-2 (FGF2) expression and release in prostate stroma (Figure 2B) [50].